Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson's disease patients with GBA1 mutations

被引：0
|
作者：
Simon, David K. [1 ]
Mendonca, Nuno [2 ]
Holenz, Joerg [3 ]
Liu, Jennifer [1 ]
Castilla-Fernandez, Guillermo [2 ]
Fonseca, Miguel M. [3 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Bial R&D Investments SA, Coronado, Portugal
[3] Bial Portela & Ca SA, Coronado, Portugal
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
POSTER 28
引用
收藏
页码：S10 / S11
页数：2
相关论文
共 50 条
  • [31] Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
    Guimaraes, P
    Kieburtz, K
    Goetz, CG
    Elm, JJ
    Palesch, YY
    Huang, P
    Ravina, B
    Tanner, CM
    Tilley, BC
    CLINICAL TRIALS, 2005, 2 (06) : 509 - 518
  • [32] GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy
    Huh, Young Eun
    Usnich, Tatiana
    Scherzer, Clemens R.
    Klein, Christine
    Chung, Sun Ju
    JOURNAL OF MOVEMENT DISORDERS, 2023, 16 (03) : 261 - 278
  • [33] Male sex accelerates cognitive decline in GBA1 Parkinson's disease
    Caminiti, Silvia Paola
    Avenali, Micol
    Galli, Alice
    Malito, Rachele
    Cuconato, Giada
    Galandra, Caterina
    Calabrese, Rosaria
    Pilotto, Andrea
    Padovani, Alessandro
    Blandini, Fabio
    Perani, Daniela
    Tassorelli, Cristina
    Valente, Enza Maria
    NPJ PARKINSONS DISEASE, 2025, 11 (01)
  • [34] GBA1 in Parkinson’s disease: variant detection and pathogenicity scoring matters
    Carolin Gabbert
    Susen Schaake
    Theresa Lüth
    Christoph Much
    Christine Klein
    Jan O. Aasly
    Matthew J. Farrer
    Joanne Trinh
    BMC Genomics, 24
  • [35] Distinctive blood alpha-synuclein profile and lysosomal alterations in Parkinson's Disease patients bearing GBA1 mutations
    Avenali, M.
    Cerri, S.
    Ongari, G.
    Pacchetti, C.
    Tassorelli, C.
    Valente, E. M.
    Blandini, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 634 - 634
  • [36] The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art
    dos Santos, Julio Cesar Claudino
    Mano, Gabriela Braga Cabrera
    da Cunha Barreto-Vianna, Andre Rodrigues
    Garcia, Tulia Fernanda Meira
    de Vasconcelos, Aline Vieira
    Sa, Caio Sergio Gomes
    de Souza Santana, Sarah Lopes
    Farias, Ana Gabriela Ponte
    Seimaru, Beatriz
    Lima, Micael Porto Portela
    Goes, Joao Vitor Caetano
    Gusmao, Camilla Teixeira Pinheiro
    Ribeiro Junior, Howard Lopes
    MOLECULAR NEUROBIOLOGY, 2024, 61 (09) : 6754 - 6770
  • [37] Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease
    Milanowski, Lukasz M.
    Oshinaike, Olajumoke
    Walton, Ronald L.
    Soto-Beasley, Alexandra I.
    Hanna Al-Shaikh, Rana
    Strongosky, Audrey J.
    Ross, Owen A.
    Wszolek, Zbigniew K.
    Ogun, Shamsideen Abayomi
    MOVEMENT DISORDERS, 2021, 36 (12) : 2971 - 2973
  • [38] Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease
    Evans, Jonathan R.
    Barker, Roger A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (08) : 1249 - 1258
  • [39] Biomarker-Driven Phenotyping in Parkinson's Disease: A Translational Missing Link in Disease-Modifying Clinical Trials
    Espay, Alberto J.
    Schwarzschild, Michael A.
    Tanner, Caroline M.
    Fernandez, Hubert H.
    Simon, David K.
    Leverenz, James B.
    Merola, Aristide
    Chen-Plotkin, Alice
    Brundin, Patrik
    Kauffman, Marcelo A.
    Erro, Roberto
    Kieburtz, Karl
    Woo, Daniel
    Macklin, Eric A.
    Standaert, David G.
    Lang, Anthony E.
    MOVEMENT DISORDERS, 2017, 32 (03) : 319 - 324
  • [40] Clinical characteristics of patients with Parkinson's disease who are carriers of severe GBA mutations
    Giladi, N.
    Orr-Urtreger, A.
    Gan-Or, Z.
    Moore, O.
    Bar Shiro, A.
    Gurevich, T.
    MOVEMENT DISORDERS, 2008, 23 (01) : S34 - S34
12345